ResearcherUniversity of North Carolina at Chapel HillNo recent work listed
Leaf Huang
Matched on ORCID iD 0000-0002-9421-8283; OpenAlex author ID A5033300046. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers
Papers 5
- Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Last author DOI 10.1016/j.tranon.2020.100856↗
- Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. Last author DOI 10.1208/s12248-020-00467-8↗
- Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. Last author DOI 10.1016/j.ymthe.2018.11.012↗
- Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. Last author DOI 10.1021/acsnano.7b01786↗
- Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Last author DOI 10.1016/j.biomaterials.2013.01.063↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manisit Das · 4 shared papers, 2017–2020 · strength 0.47
- Paper Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. DOI 10.1208/s12248-020-00467-8↗
- Paper Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. DOI 10.1016/j.ymthe.2018.11.012↗
- Paper Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. DOI 10.1016/j.tranon.2020.100856↗
- Rihe Liu · 2 shared papers, 2017–2020 · strength 0.19
- Limei Shen · 1 shared paper, 2019 · strength 0.12
- Jingjing Li · 1 shared paper, 2017 · strength 0.07
- Lei Miao · 1 shared paper, 2017 · strength 0.07
- Yuan Zhang · 1 shared paper, 2013 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.